These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 10541877)

  • 21. Quantitative relationships between pigment-related mRNA and biochemical melanoma markers in melanoma cell lines.
    Johansson M; Takasaki A; Lenner L; Arstrand K; Kågedal B
    Melanoma Res; 2002 Jun; 12(3):193-200. PubMed ID: 12140375
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Detection of occult melanoma cells in blood with a multiple-marker polymerase chain reaction assay.
    Hoon DS; Wang Y; Dale PS; Conrad AJ; Schmid P; Garrison D; Kuo C; Foshag LJ; Nizze AJ; Morton DL
    J Clin Oncol; 1995 Aug; 13(8):2109-16. PubMed ID: 7636555
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Melanoma-associated markers expression in blood: MUC-18 is associated with advanced stages in melanoma patients.
    Rapanotti MC; Bianchi L; Ricozzi I; Campione E; Pierantozzi A; Orlandi A; Chimenti S; Federici G; Bernardini S
    Br J Dermatol; 2009 Feb; 160(2):338-44. PubMed ID: 19067715
    [TBL] [Abstract][Full Text] [Related]  

  • 24. RT-PCR detection of tyrosinase, gp100, MART1/Melan-A, and TRP-2 gene transcripts in peripheral blood of melanoma patients.
    Samija M; Juretić A; Solarić M; Samija I; Bingulac-Popović J; Grahovac B; Stanec M; Oresić V
    Croat Med J; 2001 Aug; 42(4):478-83. PubMed ID: 11471202
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular and prognostic classification of advanced melanoma: a multi-marker microcontamination assay of peripheral blood stem cells.
    Schrader AJ; Probst-Kepper M; Grosse J; Kunter U; Schenk F; Franzke A; Atzpodien J; Buer J
    Melanoma Res; 2000 Aug; 10(4):355-62. PubMed ID: 10985670
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic significance of peripheral blood and bone marrow tyrosinase messenger RNA in malignant melanoma.
    Ghossein RA; Coit D; Brennan M; Zhang ZF; Wang Y; Bhattacharya S; Houghton A; Rosai J
    Clin Cancer Res; 1998 Feb; 4(2):419-28. PubMed ID: 9516931
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic value of circulating melanoma cells detected by reverse transcriptase-polymerase chain reaction.
    Palmieri G; Ascierto PA; Perrone F; Satriano SM; Ottaiano A; Daponte A; Napolitano M; Caracò C; Mozzillo N; Melucci MT; Cossu A; Tanda F; Gallo C; Satriano RA; Castello G
    J Clin Oncol; 2003 Mar; 21(5):767-73. PubMed ID: 12610172
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Diagnostic accuracy and predictive value of the tumor-associated antigen S100 in malignant melanomas: validation by whole body FDG-PET and conventional diagnostics.
    Mruck S; Baum RP; Rinne D; Hör G
    Anticancer Res; 1999; 19(4A):2685-90. PubMed ID: 10470220
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reproducibility of detection of tyrosinase and MART-1 transcripts in the peripheral blood of melanoma patients: a quality control study using real-time quantitative RT-PCR.
    de Vries TJ; Fourkour A; Punt CJ; van de Locht LT; Wobbes T; van den Bosch S; de Rooij MJ; Mensink EJ; Ruiter DJ; van Muijen GN
    Br J Cancer; 1999 May; 80(5-6):883-91. PubMed ID: 10360670
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Amplification of MelanA messenger RNA in addition to tyrosinase increases sensitivity of melanoma cell detection in peripheral blood and is associated with the clinical stage and prognosis of malignant melanoma.
    Schittek B; Bodingbauer Y; Ellwanger U; Blaheta HJ; Garbe C
    Br J Dermatol; 1999 Jul; 141(1):30-6. PubMed ID: 10417512
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular detection of metastatic pancreatic carcinoma cells using a multimarker reverse transcriptase-polymerase chain reaction assay.
    Bilchik A; Miyashiro M; Kelley M; Kuo C; Fujiwara Y; Nakamori S; Monden M; Hoon DS
    Cancer; 2000 Mar; 88(5):1037-44. PubMed ID: 10699892
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative study on the clinical use of protein S-100B and MIA (melanoma inhibitory activity) in melanoma patients.
    Schmitz C; Brenner W; Henze E; Christophers E; Hauschild A
    Anticancer Res; 2000; 20(6D):5059-63. PubMed ID: 11326668
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic significance and diagnostic value of protein S-100 and tyrosinase in patients with malignant melanoma.
    Andrés R; Mayordomo JI; Visus C; Isla D; Godino J; Escudero P; Saenz A; Ortega E; Lastra R; Lambea J; Aguirre E; Elosegui L; Marcos I; Ruiz-Echarri M; Millastre E; Sáez-Gutierrez B; Asin L; Vidal MJ; Ferrer A; Giner A; Larrad L; Carapeto FJ; Tres A
    Am J Clin Oncol; 2008 Aug; 31(4):335-9. PubMed ID: 18845991
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tumour microdissemination and survival in metastatic melanoma.
    Schrader AJ; Probst-Kepper M; Grosse J; Kunter U; Franzke A; Sel S; Atzpodien E; Buer J
    Anticancer Res; 2000; 20(5B):3619-24. PubMed ID: 11131671
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Analysis of melanoma cells in peripheral blood by reverse transcription-polymerase chain reaction for tyrosinase and MART-1 after mononuclear cell collection with cell preparation tubes: a comparison with the whole blood guanidinium isothiocyanate RNA isolation method.
    de Vries TJ; Fourkour A; Punt CJ; Ruiter DJ; van Muijen GN
    Melanoma Res; 2000 Apr; 10(2):119-26. PubMed ID: 10803712
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tyrosinase mRNA RT-PCR analysis as an additional diagnostic tool for the identification of melanoma cells in biological fluid samples other than blood: a preliminary report.
    Savoia P; Quaglino P; Osella-Abate S; Comessatti A; Nardò T; Bernengo MG
    Int J Biol Markers; 2005; 20(1):11-7. PubMed ID: 15832768
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Circulating melanoma cells and distant metastasis-free survival in stage III melanoma patients with or without adjuvant interferon treatment (EORTC 18991 side study).
    Fusi A; Collette S; Busse A; Suciu S; Rietz A; Santinami M; Kruit WH; Testori A; Punt CJ; Dalgleish AG; Spatz A; Eggermont AM; Keilholz U
    Eur J Cancer; 2009 Dec; 45(18):3189-97. PubMed ID: 19793643
    [TBL] [Abstract][Full Text] [Related]  

  • 38. RT-PCR for tyrosinase-mRNA-positive cells in peripheral blood: evaluation strategy and correlation with known prognostic markers in 123 melanoma patients.
    Farthmann B; Eberle J; Krasagakis K; Gstöttner M; Wang N; Bisson S; Orfanos CE
    J Invest Dermatol; 1998 Mar; 110(3):263-7. PubMed ID: 9506446
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The clinical utility of multimarker RT-PCR in the detection of occult metastasis in patients with melanoma.
    Taback B; Morton DL; O'Day SJ; Nguyen DH; Nakayama T; Hoon DS
    Recent Results Cancer Res; 2001; 158():78-92. PubMed ID: 11092035
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular detection of metastatic melanoma cells in cerebrospinal fluid in melanoma patients.
    Hoon DS; Kuo CT; Wascher RA; Fournier P; Wang HJ; O'Day SJ
    J Invest Dermatol; 2001 Aug; 117(2):375-8. PubMed ID: 11511319
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.